Bharat Biotech partner Ocugen to commercialize Covaxin in Mexico
As a whole virion, inactivated vaccine, it elicits robust cellular immune memory to SARS-CoV-2 and variants of concern.;
Hyderabad: Ocugen, Inc. and Bharat Biotech (BBIL) have announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen's exclusive territory to include commercialization of COVAXIN in Mexico. This gives Ocugen COVAXIN commercialization rights for all of North America.
"We're excited to commercialize COVAXIN in Mexico, as authorities there have made conquering this pandemic a major priority. After meeting with Mexico's Secretary of Foreign Affairs, Marcelo Ebrard, in Delhi, we are encouraged by the role COVAXIN can play in Mexico's continuing efforts to defeat the COVID-19 pandemic. COVAXIN is currently under review by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for emergency use among children between 2 and 18 years of age, and Ocugen is prepared to collaborate with the public health community to help their efforts. We also thank Bharat Biotech for helping make this opportunity a reality," said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer and Co-founder of Ocugen, Inc.
Read also: Bharat Biotech Covaxin recognized in Japan to facilitate travel from April 10
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.